The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses

Blood

Volumn 97, Issue 8, 2001, Pages 2420-2426

  Runyon, Kathlene ^a   Lee, Kwang ^a   Zuberek, Krystyna ^a   Collins, Mary ^a   Leonard, John P ^a   Dunussi Joannopoulos, Kyriaki ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; IMMUNOGLOBULIN G; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MIXTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOMA; MEMORY CELL; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION; THYMUS LYMPHOMA;

EID: 0035871863     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2420     Document Type: Article

References (47)

1. Tumor-antigens recognized by T lymphocytes
2. Human tumor antigens recognized by T cells
3. Role of the CD28 receptor in T-cell activation
4. The role of the CD28 receptor during T cell responses to antigen
5. Human tumor antigens are ready to fly
6. Tumor immunology: The glass is half full
7. Cancer vaccines
8. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
9. Tolerance, danger, and the extended family
10. Danger versus tolerance: Paradigms for future studies of tumor-specific cytotoxic T lymphocytes
11. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
12. Acquisition of immunologic self-tolerance
13. The B7 and CD28 receptor families
14. CD28/B7 system of T cell costimulation
15. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
16. CD28-B7 interactions in T-cell activation
17. The rote of CTLA-4 in the regulation and initiation of T-cell responses
18. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
19. Costimulation of T cells for tumor immunity
20. Manipulation of costimulatory signals to enhance antitumor T-cell responses
21. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
22. Tumor rejection after direct costimualtion of CD8+ T cells by B7-transfected melanoma cells
23. Role of B7-1 in mediating an immune response to myeloid leukemia cells
24. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML
25. Gene transfer as cancer therapy
26. CD8+ T-cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment
27. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant
28. The treatment of acute leukaemia
29. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB
30. Natural adjuvants: Endogenous activators of dendritic cells
31. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
32. Dendritic cells and the control of immunity
33. FcγR engagement in scid macrophages by soluble B7.2-IgG fusion protein induces upregulation of CD40 and other activation-related molecules
34. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation: Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production
35. Characterization of CTLA-4 structure and expression on human T cells
36. Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG
37. Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII
38. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens
39. The IgG Fc receptor family
40. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity
41. Blood lymphocyte sub-populations in breast cancer patients following post-operative adjuvant chemotherapy or radiotherapy
42. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer
43. Lymphocyte depletion during treatment with intensive chemotherapy for cancer
44. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review
45. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells
46. Interferon-gamma in the first-line therapy of ovarian cancer: A randomized phase III trial
47. Recent advances in systemic therapy for breast cancer